Evidence map›Paper›PMID 41591759›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Autophagy Activators Normalize Aberrant Tau Proteostasis and Rescue Synapses in Human Familial Alzheimer's Disease iPSC-Derived Cortical Organoids.

Sergio R Labra, Jadon Compher, Akhil Prabhavalkar, Mireya Almaraz, Claudia Cedeño Kwong, Christine Baal, Maria Talantova, Nima Dolatabadi, Julian Piña-Sanz, Yubo Wang and 14 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Organoids for disease modeling and treatment: state-of-the-art.Experimental hematology & oncology · 2026
    Review
  4. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors.

Sergio R LabraNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-4072-1131
Jadon CompherNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0009-0003-6080-1280
Akhil PrabhavalkarNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0009-0005-7083-6908
Mireya AlmarazNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.
Claudia Cedeño KwongNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0009-0003-7349-6596
Christine BaalNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0009-0004-8379-1318
Maria TalantovaNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-6460-1302
Nima DolatabadiNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.
Julian Piña-SanzNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.
Yubo WangNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.
Leonard YoonNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-8663-5757
Swagata GhatakNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0001-5462-401X
Zi GaoNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0001-5544-0693
Yuting ZhangNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.
Dorit TrudlerNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-5835-3322
Lynee MasseyNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-6908-229X
Wei LinTranslational Genomics Research Institute, Phoenix, Arizona, USA.
Anthony BalistreriNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-7409-7031
Michael BulaNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-2164-0619
Nicholas J SchorkTranslational Genomics Research Institute, Phoenix, Arizona, USA.ORCID https://orcid.org/0000-0003-0920-5013
Tony S MondalaGenomics Core, The Scripps Research Institute, La Jolla, California, USA.
Steven R HeadGenomics Core, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-5490-2750
Jeffery W KellyNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.
Stuart A LiptonNeurodegeneration New Medicines Center, The Scripps Research Institute, La Jolla, California, USA.ORCID https://orcid.org/0000-0002-3490-1259

Funding

Leadership in AD/ADRD Drug DiscoveryR35AG071734 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2021 to 2025
$5.4M
S-Nitrosylation-Induced Posttranslational Modification and Aberrant Cell Signaling in Sporadic Alzheimer's DiseaseR01AG056259 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI LIPTON, STUART A · 2017 to 2021
$3.3M
Aberrant protein S-nitrosylation mediates Gene-Environment Interactions in AD/ADRDU01AG088679 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI STUART A LIPTON, Tomohiro Nakamura · 2024 to 2026
$2.7M
Pharmacologic Lysosomal Flux Activators to Ameliorate Alzheimer's Disease and Related DementiasR01AG073418 · NIA · SCRIPPS RESEARCH INSTITUTE, THE · PI JEFFERY W KELLY · 2024 to 2026
$2.5M
NRSA Training CoreTL1TR002551 · NCATS · SCRIPPS RESEARCH INSTITUTE, THE · PI TEYTON, LUC · 2018 to 2022
$1.2M
NIA NIH HHS R01 AG056259NIA NIH HHS U01 AG088679NIH HHS R01 AG056259NIH HHS R01 AG073418NIH HHS R35 AG071734NIH HHS TL1 TR002551NIH HHS U01 AG088679
6 · The paper itself

Abstract

Alzheimer's disease (AD) is the leading cause of dementia worldwide. Nevertheless, its cellular and molecular mechanisms remain incompletely understood, partially due to inadequate disease models. To illuminate early changes in AD, we developed a cerebrocortical organoid (CO) model with improved methodology. Our COs produce excitatory and inhibitory neurons alongside glia, utilizing established isogenic wild-type and diseased human induced pluripotent stem cells (hiPSCs) carrying heterozygous familial AD mutations in PSEN1

Indexed as

Alzheimer DiseaseAutophagyInduced Pluripotent Stem CellsOrganoidsProteostasisSynapsestau ProteinsCerebral CortexHumanstau ProteinsAlzheimer's diseaseautophagycortical organoidspresenilin 1pTau oligomers

Identifiers

PMID41591759
PMCPMC13042409

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.